Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus bicalutamide versus placebo plus bicalutamide in castration-resistant metastatic prostate cancer
2008-006022-34Phase 2Terminated
- Sponsor
- Bayer
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in castration-resistant prostate cancer (CRPC) and Metastatic Prostate Cancer (mPC) comparing Sorafenib plus bicalutamide with Placebo plus bicalutamide (2 arms). Primary endpoint: Progression-free survival. Started Dec 2008; status: terminated.
02
Drugs
sorafenibbicalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on 2008-006022-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006022-34.